glp-1 news oct 21 2025 Pharmacy Pricing Update (Dec 2025) GLP-1 Weight-Loss Drug Demonstration Begins

For example, wild-type p53 replacement therapy, although widely studied and used, is unable to repair or eliminate aberrant genes and is often considered insufficiently effective in clinical practice

While investigating Ruegeria pomeroyi, we found another bacteral enzyme that holds promise: Roseovarius species 217 TMM

36k+ of glowing results

In human astrocytes, S1PR1 activation by siponimod improved Ca 2+ signaling and receptor internalization (162), while it inhibited NFB by nuclear translocation of Nrf2, a regulator of antioxidant response (64)

The primary degradation pathways for both include deamidation and oxidation (particularly of His and Trp residues)